
Twelve years of multiples investors have paid for FDC Ltd, framed against the sector median so the premium or discount is obvious at a glance.
FDC Ltd trades at a P/E of 27.35×.
Twelve years of audited numbers for FDC Ltd, switchable between annual and quarterly views, consolidated or standalone.
FDC Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,165.618 Cr and reported EPS of ₹13.85.
Disclosed business segments at FDC with their share of revenue and profit, switchable between consolidated and standalone reporting.
FDC discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Why someone would buy FDC Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
FDC Ltd's investment case rests on 5 positive markers and 6 flagged concerns drawn from the latest reported filings.
FDC Ltd exhibits a robust promoter holding of 69.7%, signifying strong internal confidence and mitigating takeover risks. This high percentage assures investors of stability and long-term commitment.
The company maintains a conservative financial strategy, reflected in its exceptionally low debt-to-equity ratio of 0.01. This minimizes financial distress risks and enhances overall financial stability.
FDC demonstrates healthy profitability with a Return on Capital Employed (ROCE) of 15.90% and Return on Equity (ROE) of 11.80%, indicating efficient capital utilization and solid operational performance.
As a player in the Pharmaceuticals sector, FDC is well-positioned to capitalize on the growing global demand for healthcare products, driven by an aging population and increasing health awareness.
FDC's relatively smaller market capitalization of ₹7166 Cr, compared to larger industry peers, presents an opportunity for higher percentage growth through market share expansion and strategic product diversification.
FDC's stock price shows considerable volatility, with a 52-week high of ₹559 and a low of ₹359, indicating market uncertainty and potential risk for investors seeking stable returns.
Despite positive profit growth, FDC's Price-to-Earnings (PE) ratio of 26.60 is relatively high compared to some industry peers, suggesting a potential overvaluation and susceptibility to price corrections.
The company exhibits notably low quarterly sales growth of 1.59% and quarterly profit growth of 1.94%, significantly lagging behind many industry peers and raising concerns about competitive performance.
FDC faces intense competition from larger, well-established pharmaceutical companies like Sun Pharma and Divi's Lab, potentially limiting its market share growth and pricing power in key segments.
The highly regulated pharmaceutical industry exposes FDC to risks from adverse policy changes, stricter compliance requirements, and potential pricing pressures, impacting future revenue and profitability.
Trim if P/E re-rates above 36. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — FDC Ltd is highlighted for quick read-across.
| Company Name |
|---|
Aarey Drugs & Pharmaceuticals Ltd |
Aarti Drugs Ltd |
Aarti Pharmalabs Ltd |
Ajanta Pharma Ltd |
Akums Drugs & Pharmaceuticals Ltd |
Albert David Ltd |
Alivus Life Sciences Ltd |
Alkem Laboratories Ltd |
Alpa Laboratories Ltd |
Amrutanjan Health Care Ltd |
Alembic Pharmaceuticals Ltd |
Astrazeneca Pharma India Ltd |
Aurobindo Pharma Ltd |
Bafna Pharmaceuticals Ltd |
Bajaj Healthcare Ltd |
Bal Pharma Ltd |
Biocon Ltd |
Biofil Chemicals & Pharmaceuticals Ltd |
Bliss GVS Pharma Ltd |
Blue Jet Healthcare Ltd |
Brooks Laboratories Ltd |
Caplin Point Laboratories Ltd |
Cipla Ltd |
Cohance Lifesciences Ltd |
Concord Biotech Ltd |
Dishman Carbogen Amcis Ltd |
Divis Laboratories Ltd |
Dr Reddys Laboratories Ltd |
Emcure Pharmaceuticals Ltd |
ERIS Lifesciences Ltd |
FDC LtdCurrent Stock |
Gland Pharma Ltd |
Glaxosmithkline Pharmaceuticals Ltd |
Glenmark Pharmaceuticals Ltd |
Granules India Ltd |
Gufic BioSciences Ltd |
Haleos Labs Limited |
Hester Biosciences Ltd |
Hikal Ltd |
Indoco Remedies Ltd |
Ind-Swift Laboratories Ltd |
Innova Captab Ltd |
IOL Chemicals & Pharmaceuticals Ltd |
Ipca Laboratories Ltd |
Jagsonpal Pharmaceuticals Ltd |
J B Chemicals & Pharmaceuticals Ltd |
Jubilant Pharmova Ltd |
Kilitch Drugs (India) Ltd |
Kopran Ltd |
Krebs Biochemicals & Industries Ltd |
Lasa Supergenerics Ltd |
Laurus Labs Ltd |
Lincoln Pharmaceuticals Ltd |
Lupin Ltd |
Lyka Labs Ltd |
Mangalam Drugs and Organics Ltd |
Mankind Pharma Ltd |
Marksans Pharma Ltd |
Medicamen Biotech Ltd |
Medico Remedies Ltd |
Morepen Laboratories Ltd |
Natco Pharma Ltd |
Nectar Lifescience Ltd |
Neuland Laboratories Ltd |
NGL Fine Chem Ltd |
OneSource Specialty Pharma Ltd |
Orchid Pharma Ltd |
Ortin Global Ltd |
Panacea Biotec Ltd |
Pfizer Ltd |
Procter & Gamble Health Ltd |
Piramal Pharma Ltd |
RPG Life Sciences Ltd |
Sai Life Sciences Ltd |
Sanofi India Ltd |
Sanofi Consumer Healthcare India Ltd |
Senores Pharmaceuticals Ltd |
Shilpa Medicare Ltd |
Sigachi Industries Ltd |
SMS Pharmaceuticals Ltd |
Solara Active Pharma Sciences Ltd |
Sun Pharma Advanced Research Company Ltd |
Strides Pharma Science Ltd |
Sun Pharmaceutical Industries Ltd |
Supriya Lifescience Ltd |
Syncom Formulations (India) Ltd |
Themis Medicare Ltd |
Torrent Pharmaceuticals Ltd |
Unichem Laboratories Ltd |
Valiant Laboratories Ltd |
Venus Remedies Ltd |
Vineet Laboratories Ltd |
Viyash Scientific Ltd |
Wanbury Ltd |
Windlas Biotech Ltd |
Wockhardt Ltd |
Zim Laboratories Ltd |
Zydus Lifesciences Ltd |
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for FDC Ltd — derived from the live tape, not yesterday's close.
FDC Ltd last traded at ₹381 with an intraday range of ₹379.4–₹399.95 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 435.27 | +54.27 | +14.24% |
| R3 | 414.72 | +33.72 | +8.85% |
| R2 | 407.33 | +26.33 | +6.91% |
| R1 | 394.17 | +13.17 | +3.46% |
| PIVOT | 386.78 | 5.78 | 1.52% |
| CURRENT | 381.00 | — | — |
| S1 | 332.52 | -48.48 | -12.73% |
| S2 | 353.07 | -27.93 | -7.33% |
| S3 | 366.23 | -14.77 | -3.88% |
| S4 | 373.62 | -7.38 | -1.94% |
FDC is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 382.15 ~ 399.95
Trading Below opening range, showing Bearishness
Daily traded volume and delivery percentage for FDC Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in FDC Ltd stood at 45.3% of traded volume, against a 20-day average of 51.0%.
Filings FDC sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Every dividend, stock split and bonus issue FDC has declared, sequenced by announce and record date.
FDC corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
What FDC Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
FDC Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: FDC, BSE: 531599.

FDC Limited is a pharmaceutical company with a long history, established in 1936 and headquartered in Mumbai, India. Its core business revolves around the manufacture and marketing of a wide range of pharmaceutical products both domestically within India and internationally. The company's product portfolio is extensive and caters to various therapeutic areas, demonstrating a diverse approach to market segments.
FDC's product offerings span a considerable spectrum of therapeutic categories. These include anti-infectives to combat infections, gastrointestinal medications for digestive health, and ophthalmic products for eye care. Furthermore, they produce vitamins, minerals, and dietary supplements targeting overall health and wellness. Their product line also extends to treatments for cardiac conditions, diabetes, respiratory illnesses, gynecological issues, dermatological problems, and pain management (analgesics). Beyond traditional pharmaceuticals, they also manufacture and market a range of nutraceuticals, including anti-oxidants, balanced energy and protein drinks.
The company leverages a portfolio of established brand names to market its products. These brands, such as Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal, represent a significant investment in brand recognition and consumer trust. This multi-brand strategy likely helps FDC target diverse market segments and consumer needs within the pharmaceutical and nutraceutical sectors.
In addition to finished pharmaceutical products, FDC also manufactures active pharmaceutical ingredients (APIs). This vertical integration provides the company with greater control over its supply chain and potentially allows for cost efficiencies and enhanced product quality. By controlling the production of core components, FDC likely mitigates risks associated with reliance on external API suppliers.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of FDC Ltd (FDC) is ₹381. Today, the stock has declined by ₹19.55 (4.88%), trading in a range of ₹379.4 to ₹399.95. The stock opened at ₹392 with a trading volume of 6,31,093 shares.
FDC Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,165.62 crores, P/E ratio of 27.35, ROE of 2.85%, and ROCE of 15.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of FDC Ltd (FDC) is ₹527.8, while the 52-week low is ₹312.95. Currently trading at ₹381, the stock is 31.7% away from its 52-week low and 27.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy FDC Ltd stock at ₹381 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.35 and P/B ratio of N/A. Today's performance shows a loss of 4.88%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
FDC Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹381, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
FDC Ltd's key financial metrics include: P/E Ratio: 27.35, P/B Ratio: N/A, ROE: 2.85%, ROCE: 15.90%, Dividend Yield: 0.00%, EPS: ₹13.85, Book Value: ₹140.11, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹6,165.62 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
FDC Ltd stock opened at ₹392 and is currently trading at ₹381, showing a decline of ₹19.55 (4.88%). The intraday high is ₹399.95 and low is ₹379.4. The trading volume stands at 6,31,093 shares, indicating moderate market participation today.
FDC Ltd has a Price-to-Earnings (P/E) ratio of 27.35, which means investors are willing to pay ₹27.35 for every ₹1 of earnings. With an EPS of ₹13.85, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about FDC Ltd (FDC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.